Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPERNICO: Keytruda and Actemra in COVID-19 Pneumonia
NCT04335305Phase 2Terminated
- Sponsor
- MEDSIR
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in coronavirus disease 2019 (COVID-19), viral pneumonia, sponsored by MEDSIR. Started Apr 2020; status: terminated.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on NCT04335305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335305.